Health & Beauty

One million doses of 13 valent pneumococcal polysaccharide conjugate vaccine developed by Watson biology were sent from Yuxi, Yunnan to Morocco on the 21st. This indicates that the 13 valent pneumococcal polysaccharide conjugate vaccine produced in China began to go to the overseas market.

Watson biological's 13 valent pneumococcal polysaccharide conjugate vaccine was approved for marketing in 2019. It is the first 13 valent pneumonia conjugate vaccine in China and the second in the world. It is mainly suitable for infants and children aged 6 weeks to 5 years (before the birthday of 6 years), It can be used to prevent infectious diseases caused by 13 serotypes (type 1, 3, 4, 5, 6a, 6b, 7F, 9V, 14, 18C, 19A, 19F and 23F) pneumococcus contained in the vaccine.

The batch of vaccines exported this time is the order of marocvax company in Morocco, with a total of 1 million doses. At present, Watson biological's 13 valent pneumonia conjugate vaccine has been included in Morocco's expanded immunization plan to protect millions of children from life-threatening diseases. According to the distribution agreement, marocvax promised to purchase 2 million doses of finished products or stock solution of 13 valent pneumonia conjugate vaccine from Watson biology every year for five consecutive years.